A Revolution in Treatment for Hepatitis C Infection: Mitigating the Budgetary Impact.

Clicks: 248
ID: 69173
2016
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #58 of 78 articles by views in plos medicine

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
In a Perspective accompanying Hill and colleagues, Elliot Marseille and James Kahn compare the history of pricing and availability of ART for HIV with that of the new HCV drugs and discuss strategies for providing treatment in LMIC even in the face of high costs.
Reference Key
marseille2016aplos Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Marseille, Elliot;Kahn, James G;
Journal plos medicine
Year 2016
DOI
DOI not found
URL
http://europepmc.org/articles/PMC4886960?pdf=render
Keywords
Medicine business electronic computers. computer science probabilities. mathematical statistics

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.